Skepticism About Biotechnology Isn’t Anti-Science – Slate Magazine

AquAdvantage salmon.

AquAdvantage

Keep Frankenfish off my Dish! a protesters sign read. Another, adorned with six red hearts, suggested that real people love real salmon. A couple of years ago, protests against the approval and sale of genetically modified salmon targeted the Food and Drug Administration and supermarket chains across the country, attempting to halt the approval and sale of the AquAdvantage salmonan Atlantic salmon modified with DNA from the Chinook salmon and the ocean pout. The borrowed genetic material lets the fish grow year-round and reach market size in half the time as its natural counterpart, but its also spurred passionate public debate.

In November 2015, the FDA approved the AquAdvantage salmon as the first genetically engineered animal for human consumption. According to the hype, the AquAdvantage salmon could help with reducing global hunger, decreasing the carbon footprint of aquaculture (the cultivation of fish and other aquatic life), and shoring up dwindling wild fish stock. The regulatory process behind the approval of the AquAdvantage salmon took almost 20 years.

But the approval was quickly followed by a flurry of controversy and charges of insufficient consideration of key issues. A consortium of environmental groups lead by Earthjustice and the Center for Food Safety sued the FDA for approving the AquAdvantage salmon, in their words, without considering or fullydisclosing the environmental and other risks of this unprecedented decision. Two months after the approval, Congress also threw a wrench in the works by adding a rider to a spending bill that tasked the FDA with spending not less than $150,000 to develop labeling and implement a program of consumer disclosure for the fish before it could be made available for sale. As a result the fish is not yet anywhere near U.S. dinner plates, caught up in a seemingly endless process of contestation, with no clear end in sight.

To many in bioscience and biotechnology circles, this is a case of politics contaminating science. In an open letter to President Obama in 2014, a group of concerned international scientists and global technology company executives argue this point:

These scientists and others offer a picture of a Manichean world divided into those who are for scientific and technological progress and those who are against ita representation of the world that we have been seeing more and more of lately in reports of a war on science. But drawing this line is dangerous. The real problem here is the regulatory process itself, which forces dissent to take the narrow form of challenges to scientific data and methodology and ignores other questions about whats at stake.

The FDA approval process for the AquAdvantage salmon took longer and included more opportunities for public comment than most products the FDA reviews. This unique openness to public input was balanced by a careful parsing of what counts as scientifically and contextually relevant and what does not. The agency received 38,000 comments in response to its draft assessment alone, but it determined that just 90 were worth considering. The remaining comments were discounted as irrelevant because they did not directly address the details of the regulation process, or they raised issues beyond the mandate of the agency. These disregarded comments focused on a wide range of concerns, including patenting and ownership regimes of seed and crops; how deploying genetically modified corn and soy would affect the United States image around the world; continuing failures of existing market configurations to address inequality and food distribution; and the long history of multinational corporations central to the commercialization of biotechnologies, such as Monsanto, intentionally obscuring the negative impacts of their chemical products and byproducts while undermining human health.

Your Cheat-Sheet Guide to Synthetic Biology

What Exactly Is Synthetic Biology? Its Complicated.

Can You Patent an Organism? The Synthetic Biology Community Is Divided.

The U.S. Regulations for Biotechnology Are Woefully Out of Date

Synthetic Biology and Queer Theory Are Cutting Down the Tree of Life You Learned About in School

Being Skeptical About Biotechnology Doesnt Make You Anti-Science

So the FDA is not the forum for deliberation on the meaning of giving entry to this new form of life into our environment, grocery stores, and dining rooms. But what is? The FDA approval process is the only existing avenue for public consideration of technological innovation of this kind. Accordingly, the agencys narrow reading of what kinds of input are relevant represents a significant dismissal of a broad range of relevant concerns.

Some might read the vast public preoccupation with a broad set of social, political, and economic issues as the contamination of science with politics. But I would suggest that this is actually a case of the reverse problem: seemingly endless conflict around the AquAdvantage salmon reflects the limitation of using narrow scientific terms to address questions of broad social, political, and economic significance. As things stand, the only legitimate way to engage in debates about the entry of the AquAdvantage salmon and other genetically modified organisms into our environments, meals, intellectual property regimes, and beyond is to contest its approval at the level of regulatory science. When the system asks the public to limit objections to narrow technical concerns, it undermines regulatory legitimacy and stultifies democratic debateand perhaps most importantly, it contributes to the problematic discourse around science itself. When our modes of public deliberation strictly define what counts as a legitimate view on these issues, we end up portraying a good portion of the population as against science, when that in fact could not be further from the truth.

The vast majority of people in the world, not being scientists or angel investors, have no say over the technological trajectories that will shape our world and our lives. We are instructed to continue funding basic science and patiently wait and watch as the world is transformed around us. Scientists often dismiss resistance to the AquAdvantage salmon and other biotechnologies as borne of scientific ignorance. But its a lot easier to understand peoples reluctance if you realize that the debate is about much broader questions than science alone can answer.

To position science on one side of these debates is not only patently false but detrimental to public discourse.

As the first genetically engineered animal developed for human consumption, the AquAdvantage salmon can be understood as an early form or precursor to products of more advanced practices of synthetic biology. Even as the power and precision of these techniques increases and the particular technical challenges associated with the salmon are left behind, the core issues and deep public resistance around the AquAdvantage salmon will likely persist and haunt continued efforts to reshape environments, economies, and human life through the biological sciences. Synthetic biology is billed as having the potential to transform the world in a way that will disrupt prevailing economic and geopolitical paradigms and reshape the very fabric of life. The one thing both sides of the fishy debate seem to agree on is that the AquAdvantage salmon is a pioneer technology, and what happens to this fish could set the stage for the role that biotechnology will play in our food system in the century to come. As one commentator opined for the New York Times:

This framing suggests that biotechnological innovation is a necessary and unmitigated good. But for many, the prospect of a world radically altered by biotechnology conjures past experiences in which scientific progress didnt go as plannedlike the devastation and political instability ushered in by nuclear weapons. Similarly, to some, a dam looks like progress, development, and economic prosperity. But to others, it looks like the violent end of a way of life, heralded by the destruction of ecosystems and entire species.

The debates over the AquAdvantage salmon arent narrow and technicaltheyre multifaceted, laden with questions of political, economic, and social values. They are about what kind of world we want to live in and what types of transformations are beneficial, desirable, and helpfuland for whom. To position science on one side of these debates is not only patently false but detrimental to public discourse and productive political deliberation.

Nonetheless, resistance to biotechnologies is often framed as a problem of the uneducated masses meddling in areas where they dont belong. The open letter to Obama by the concerned scientists and technologists, for example, claims:

Characterizing legitimate concerns about what kinds of technologies enter and help shape our world as anti-science is more likely to alienate than inspire everyday Americans to identify with this vision of what science can do, and to believe in it.

The long journey of the AquAdvantage salmon may turn out to have been a waste of time, energy, and resources on all sides, but perhaps we can make it productive in one way. Understanding the limitations of the process can help us think critically about how decision-making about synthetic biology going forward might be more open to a broader set of concerns and voices much earlier in the innovation process. The way forward is not drawing battle lines between those who are for or against science and closing down regulatory processes to all but the narrowest risk-based considerations. Rather, we should be forming and expanding spaces for a wide range of participants in creatively considering how to solve societys biggest challenges. We need new ways of thinking and talking about technological promise and possibility in the world that we live in.

This article is part of the synthetic biology installment of Futurography, a series in which Future Tense introduces readers to the technologies that will define tomorrow. Each month, well choose a new technology and break it down. Future Tense is a collaboration among Arizona State University, New America, and Slate.

See the original post:
Skepticism About Biotechnology Isn't Anti-Science - Slate Magazine

SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing – Yahoo Finance

WEST LAFAYETTE, Ind., April 26, 2017 /PRNewswire/ --SSCI, a division of Albany Molecular Research Inc. (AMRI), has been recognized by Global Health & Pharma (GHP) magazine as the winner of the 2017 Biotechnology Award for Best Global Research & Manufacturing Company in the United States.

"I am truly honored to accept this award on behalf of our dedicated team that is deeply committed to the mission of helping our clients achieve their product development goals and generate valuable intellectual property day in and day out," said David A. Engers, Ph.D., general manager at SSCI. "We are grateful to GHP for recognizing our commitment to client service and data integrity in order to provide unmatched value to the industries we have served for more than a quarter century."

GHP magazine recognizes that the biotechnology industry is increasingly viewed as being the frontline of medical science, and as this movement continues to gain momentum the publication is committed to following the most game-changing advances and revolutionary developments that will form the healthcare world for years to come.

Nathan Angell, GHP awards coordinator, expressed pride in every one of the award winners, "This award recognizes the hard work and dedication of the firms, such as SSCI, and the individuals behind them, that are driving innovation in this vital market. It has been my honor to recognize these dedicated professionals and I would like to wish them the very best of fortunes for the future."

About SSCIAMRI SSCI, LLC (SSCI), a division of AMRI, provides industry leading contract solid-state and analytical testing services and exists to help companies in the pharmaceutical, food, agrochemical, and other chemical industries develop better products and get them to market more quickly. SSCI provides comprehensive cGMP research and analytical services in the characterization and chemistry of solid materials, with particular expertise in small and large molecules being investigated for pharmaceutical use.To learn more about SSCI's solid-state and analytical chemistry services and capabilities,please contact 1-800-375-2179 | http://www.ssci-inc.com.

About GHP MagazineGlobal Health and Pharma (GHP) magazine is a global, information-sharing platform and a multi-disciplinary members community. The publication was established to enhance communication networks and collaboration across all themes and disciplines within three main categories; Human, Animal and Environmental Health.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ssci-receives-a-2017-biotechnology-award-for-global-research-and-manufacturing-300445541.html

View original post here:
SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing - Yahoo Finance

3D Systems and United Therapeutics to Develop 3D Printing Biotechnology for Solid-Organ Scaffolds – 3DPrint.com

No matter how many times I read or write about it, I am still overwhelmed and amazed when I see what 3D printing technology is currently able to do for the medical field, and what it has the potential to do down the line. Today, 3D Systems, a company thats nearly synonymous with precision healthcare capabilities, and biotechnology company United Therapeutics Corporation announced a joint plan to develop solid-organ scaffolds for use in human transplants. The multi-year development and collaboration is a good fit, combining 3D Systemshealthcare and 3D printing expertise with the organ manufacturing and regenerative medicine proficiency of United Therapeutics, which is also a member of the consortium that makes up the Advanced Tissue Biofabrication Manufacturing USA Institute.

Vyomesh Joshi, CEO of 3D Systems, said, As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting.We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the caliber of United Therapeutics to provide healthcare solutions of the future.

In addition to collaborating with United Therapeutics, which is focused on developing and commercializing products that address the medical needs of patients living with chronic and life-threatening conditions, 3D Systems will also work with its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, which is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Through several technologies that expand the supply or delay the need for transplantable organs, Lung Biotechnology PBC addresses head-on the critical shortage of transplantable lungs, and other organs, in the US. Withthe subsidiary also on board with the 3D Systems collaboration, an additional technology alternative can be added to United Therapeutics pursuit of an unlimited supply of organs for human transplantation.

Dr. Martine Rothblatt, PhD, Chairman and CEO of United Therapeutics, said, Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care problem.Indeed, we expect one personalized organ transplant will avoid years of health care spending on palliative medical therapies.

The focus of the joint bioprinting agreement is to develop 3D printing systems for solid-organ scaffolds, and with Lung Biotechnology PBCs participation, obviously the first thing the companies will tackle is lung scaffolds. Scaffolds are an important part of the bioprinting process, as they give printed cells, and organs, a structure to develop and grow on. So determining the correct way to create a scaffold is incredibly important to the success of these endeavors.

Combiningthe resources of United Therapeutics and 3D Systems transforms our capability to tackle this difficult challenge.This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems as well as the domain knowledge of our technical partners at Lung Biotechnology PBC, said Chuck Hull, Executive Vice President and Chief Technology Officer for 3D Systems.

The 3D printing system that 3D Systems and United Therapeutics hope to create will be targeting collagen, along with other building block proteins, as the raw materials for the scaffolds themselves. In turn, Lung Biotechnology PBC will then celluralize the scaffolds using patient-specific biological material, which includes re-differentiated stem cells.

Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs.By cellularizing scaffolds created with 3D Systems printers with a patients own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation, said Dr. Rothblatt.

[Image: OPTN]

Excerpt from:
3D Systems and United Therapeutics to Develop 3D Printing Biotechnology for Solid-Organ Scaffolds - 3DPrint.com

Use of biotechnology must to attain food security: Bosan | Pakistan … – Pakistan Today

Around 130 national and international academicians and scientists hailing from seven different countries including Turkey, Tunisia, Sudan, Iran, Sri Lanka, and Uzbekistan attended a workshop held here to promote the safe use of modern biotechnology to attain the goal of food security and defeating hunger and poverty.

Minister for Food Security and Research Sikandar Hayat Khan Bosan inaugurated the 3rd International Conference on Agriculture, Food Security and Biotechnology on Wednesday.

The 2-day event being held at the National Agriculture Research Center, Islamabad, is jointly organised by Commission on Science and Technology for Sustainable Development in the South (COMSATS), ISESCO and Pakistan Agricultural Research Council (PARC).

Addressing the audiences, the minister said that it was time that the countries of the region should encourage and support smart agricultural practices.

He said safe use of modern biotechnology was needed to enhance agricultural production and get rid of malnutrition and starvation. The minister pledged full support for agricultural production which was the backbone of economy with sustainable food security.

Dr Ghulam Muhammad Ali, Member Coordination and Monitoring, PARC, Islamabad, noted that advances in science and technology were the need of time for food security and safety. Noting the hunger still prevailing in various parts of the world, he opined that biotechnology was the basis of production of vast variety of transgenic and genetically modified crops which can solve the problem of hunger.

He said that the conference having similar agenda was good for the developing countries as it would open ways for research, collaboration and capacity building.

Speaking on the occasion, Dr Kauser Malik, Department of Biological Sciences, FC College Lahore, mentioned that it was our fear of unknown that kept the human beings away from adapting new technologies and advocated the use of genetically modified crops for addressing hunger.

In his message, Dr SM Junaid Zaidi, Executive Director COMSATS, said that despite major developments around the globe, many areas struggle with challenges of starvation and malnutrition. Even the developed countries cannot engage in bigger pursuits without ensuring food security. Mentioning the importance of biotechnology in agriculture, he noted that biotechnological influence on food production and agriculture is undeniable especially for countries like Pakistan with fertile lands and good weather conditions.

The message from Director General ISESCO, HE Dr. Abdulaziz Othman Altwaijri, noted that there was a dire need to provide an enriching and engaging environment to foster crop science research towards new and improved livelihood opportunities and sustainable food security. He considered collaborations in this regard necessary and appreciated the cooperation between ISESCO and COMSATS.

Shields were given to the esteemed participants who came from different countries for the conference.

Continue reading here:
Use of biotechnology must to attain food security: Bosan | Pakistan ... - Pakistan Today

3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants – TCT Magazine

3D Systems has announced a bioprinting agreement with United Therapeutics which will see the two companies develop solid-organ scaffolds for human transplants with 3D printing.

Combining their respective expertise in 3D printing and regenerative medicine and organ manufacturing, the collaboration will remain for a number of years.

The agreement will pit 3D Systems personnel alongside professionals from a United Therapeutics subsidiary, Lung Biotechnology PBC. Since the collaboration will primarily focus on the development of 3D printing systems for solid-organ lung scaffolds, Lung Biotechnology PBC is seen as best placed to work with 3D Systems.

The printing system will target collagen, and other building block proteins, as scaffold raw materials. Lung Biotechnology PBC will cellularize the scaffolds with patient-specific biological material, including re-differentiated stem cells.

Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs, said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. By cellularizing scaffolds created with 3D Systems printers with a patients own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation.

3D Systems is a company with a wealth of experience in the medical sector. Its precision healthcare capabilities include simulation, virtual surgical planning, and the printing of medical and dental devices. Two of 3D Systems leading executives are not only confident in their companys own knowledge of the medical 3D printing sector, but also of United Therapeutics own expertise. Though conceding the challenge is not straight forward, the pair foresee new solutions being born from the partnership.

As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting, said Vyomesh Joshi, Chief Executive Officer, 3D Systems. We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the calibre of United Therapeutics to provide healthcare solutions of the future.

Chuck Hull, Executive Vice President, Chief Technology Officer, 3D Systems, added: Combining the resources of United Therapeutics and 3D Systems transforms our capability to tackle this difficult challenge. This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems as well as the domain knowledge of our technical partners at Lung Biotechnology PBC.

Meanwhile, the collaboration and joint development will add another technology alternative to United Therapeutics pursuit of an unlimited supply of organs for human transplantation.

Dr Rothblatt concludes: Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care program. Indeed, we expect one personalised organ transplant will avoid years of health care spending on palliative medical therapies.

See the rest here:
3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants - TCT Magazine

United States Biotechnology Industry – Porter’s Five Forces Strategy … – Business Wire (press release)

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "United States Biotechnology Industry - Porter's Five Forces Strategy Analysis" report to their offering.

The rapidly emerging biotechnology industry is a critical element of national power. Advances in biotechnology are resulting in novel biomedical and pharmaceutical products and processes that are relieving human suffering, improving health, and increasing the quality of life for the world's citizens. The majority of U.S. biotechnology firms are pursuing markets in human health care.

The research analyzes the US Biotechnology industry in the Michael Porter's Five Forces Analysis. It uses concepts developed in Industrial Organization (IO) economics to derive five forces that determine the competitive intensity and therefore attractiveness of a market.

Apart from the Porter's Five Forces analysis, the report also analyzes the biotechnology industry in the US in a brief profile.

Key Topics Covered:

A. Executive Summary

B. Introduction to the Industry

B.1 Industry Definition

B.2 What is Biotechnology?

B.3 Industry Structure

B.4 Industry Size

C. Porter's Five Forces Strategy Analysis

C.1 Bargaining Power of Buyers

C.2 Bargaining Power of Suppliers

C.3 Competitive Rivalry in the Industry

C.4 Threat of New Entrants

C.5 Threat of Substitutes

D. Conclusion

E. Glossary of Terms

For more information about this report visit http://www.researchandmarkets.com/research/pgkqzr/united_states

See original here:
United States Biotechnology Industry - Porter's Five Forces Strategy ... - Business Wire (press release)

The U.S. Regulations for Biotechnology Are Woefully Out of Date – Slate Magazine

CRISPR is a gene-editing tool that enables scientists to do things like turn off the enzyme that makes mushrooms turn brown when bruised or cut.

Brand X Pictures/Thinkstock

In April 2016, an unlikely thing made headlines: the common white button mushroom.

Gene-Edited CRISPR Mushroom Escapes US Regulation, wrote Nature.

Whats a GMO? Apparently Not These Magic Mushrooms, wrote Grist.

And from MIT Technology Review: Who Approved the Genetically Engineered Foods Coming to Your Plate? No One.

The white button mushroom in question looked like any other in the grocery store, with one imperceptible difference: It was missing a gene that codes for an enzyme called PPO, or polyphenol oxidase, which makes mushrooms turn brown when theyre bruised or cut. Scientists at Pennsylvania State University essentially turned off this PPO geneone of six in the mushroomwith a new gene-editing tool called CRISPR, or clustered regularly interspaced short palindromic repeats. CRISPR is a bit like a biological word processor. It zooms to a specific genetic sequence in any living thingthe biotech equivalent of using Ctrl+F. Then, the tool can add, delete, or replace genetic information like an editor tweaking a sentence.

While the Penn State scientists used biotechnology to manipulate the mushrooms genes, their work didnt trigger government oversight, in part because current law doesnt necessarily apply to food made with CRISPR. The case highlights a chronic challenge with biotechnology regulation: It cant keep up with the fast pace of innovation. No surprise there: The relevant laws havent had a proper update in more than 30 years.

Not only that, the regulations are cobbled together, says Jaydee Hanson, a senior policy analyst at Center for Food Safety, an advocacy group. If you were writing a sci-fi novel, your editor would say, Thats just too unbelievable. No one would ever do it that way.

Your Cheat-Sheet Guide to Synthetic Biology

What Exactly Is Synthetic Biology? Its Complicated.

Can You Patent an Organism? The Synthetic Biology Community Is Divided.

The U.S. Regulations for Biotechnology Are Woefully Out of Date

The CRISPR mushroom doesnt appear to pose a health or environmental threat, so in this case the regulatory gaps may not matter. But what about a potentially damaging biotech creation made the same way? How will we regulate synthetic organisms made with technologies that dont yet exist? These questions arent just about food, as important as that istheyre also key for any biotech or synbio product, such as mosquitoes engineered to curb diseases and microbes made from scratch.

Depending on whom you talk to, the CRISPRd mushroom isnt strictly defined as synthetic biology. Still, genetic technology exists on a continuum, and the regulatory conundrum the mushroom raises is relevant to any organism tweaked in a lab.

Over the past two years, policymakers had a fleeting chance to improve biotech lawsand they missed it. Now that were in the wild and unpredictable world of the Trump administration, the future of biotech regulation is a big fat question mark.

To understand biotech regulations, we have to go back in time to 1986, when the cool kids were pegging their jeans, Top Gun was in the theaters, and Lionel Richie and Bananarama dominated the airwaves.

Another trend back then: recombinant DNA. Scientists discovered this genetic engineering tool in the early 1970s, when they first swapped genes from one species into another using the bacteria E. coli. The discovery was a landmark for biotechnology. By the 1980s, companies were commercializing microbes and plants made with recombinant DNA, and regulators ears perked up.

The decision fell to the White House Office of Science and Technology Policy, which has two main jobs. The first is to advise the president on matters of science, tech, and engineering. The second is to help coordinate multiple agencies on scientific policy. Rather than writing a new law, the OSTP decided to fit genetically engineered products into existing laws. The result, called the Coordinated Framework for the Regulation of Biotechnology, published in June 1986. A small update in 1992 didnt change much.

Under the coordinated framework, regulation falls to the Environmental Protection Agency, the U.S. Department of Agriculture, and the Food and Drug Administration.

Yang Labs

The EPAs job is to protect human health and the environment. Several laws allow the EPA to do this, but the two relevant for biotech regulation relate to pesticides and toxic materials. Under the coordinated framework, the EPA can regulate any biotech organisms that produce these chemicals in some way. A genetically engineered crop that makes its own insecticide, for example, would trigger EPAs oversight on pesticides, while a microbe altered to produce biofuel would trigger the rules for potentially toxic chemicals.

The USDAs job, in part, is to protect U.S. agriculture. When it comes to biotech, the relevant laws that give USDA power relate to plant health. When the coordinated framework first published, the state-of-the-art genetic engineeringrecombinant DNAused microbes to deliver new genes. In crops, for example, scientists used agrobacterium, a bacterium that can infect plants. Its a weird way to apply the lawthese microbes arent likely to hurt crops. But the microbes are technically plant pathogens, which gives the USDA the authority to regulate any crop made this way.

As for the FDA, part of its job is to keep our food safe. Under the coordinated framework, companies proposing to sell a biotech food may submit to a voluntary safety review, to prove that its not going to poison anyone or give them a horrifying allergic reaction.

The original coordinated framework was a messy solution, but it worked OK for the technologies that were available back in the 80s and 90s. Today? Not so much. Take the CRISPRd mushroom. Because the mushroom doesnt produce pesticides or potentially toxic chemicals, the EPA had no reason to regulate it. The Penn State scientists who made the mushroom didnt use microbes to deliver DNACRISPR doesnt require that stepand so their work didnt trigger USDA oversight. As for the voluntary FDA review, the agency hasnt published anything on the mushroom so far.

Policymakers knew the coordinated framework was rickety even before the mushroom came along. In July 2015, the Obama administration asked the OSTP to take another look at the policy to ensure that the system is prepared for the future products of biotechnology.

To do this, the OTSP proposed three steps. One was to commission a report from the National Academies of Science exploring new biotech that may come out over next five to 10 years (more on this in a minute). For the other two, the agencies had to update their role in current biotech regulation and spell out a long-term strategy for future products.

The update took more than a year and included a series of closed and public meetings. A draft published last September, and the final version came out in early January. It was a lot of work for an underwhelming document. Rather than update the coordinated framework, the document lists a series of hypothetical biotech products and explains how each agency might regulate them. But none of the hypothetical exercises explored how products made with new technologies, like the CRISPR mushroom, may fit the current rules.

Its hard to imagine President Trump giving biotech much thought.

I thought it was a missed opportunity, says Jennifer Kuzma, a professor of science and technology policy and co-director of the Genetic Engineering and Society Center at North Carolina State University.

A better approach may have been to blow the whole thing up and start over: Write a new law that could adapt to future technologies. Such a law would have a broad scope that could capture any biotech or synbio product, regardless of how its made. Ideally, the law would also be more elastic when it comes to risk. We should let the traits of the organism determine the level of regulation, says Greg Jaffe, biotechnology director for the Center for Science in the Public Interest. Things that are potentially more risky should get more scrutiny, and things that are potentially less risky should have less scrutiny.

Of course, writing new biotech laws would require legislative approvala tough job in any year, made even more unlikely in todays hyperpartisan, dysfunctional Congress.

But there are other ways biotech laws could change. Remember, the OSTP also tasked the agencies with a long-term strategy for future biotech products. In January, just days before Obama left office, the FDA published draft guidance on regulating genetically altered animals, which will include CRISPR and other new technologies, as well as guidance on gene-edited foods and mosquitoes.

Around the same time, the USDA proposed new rules on biotech plants. In addition to potential plant pests that it already monitors, USDA wants to use a law that lets it regulate noxious weedsplants that pose a threat to the environment, the economy, or society, such as invasive species. Using this law would broaden the agencys ability to do risk assessments on genetically engineered products. The new rules would also allow the USDA to revise previous decisionsfor example, if there is evidence that an approved product is causing unexpected ecological damage.

Before the FDA and USDA proposals can move forward, theyll go through public comment periods, which end on June 19. The draft changes can help fix some of the problems with the coordinated framework, says Kuzma. Theyre not the entire solution, but theyre patches.

The other piece that could inform new policy is the National Academies report on biotech, which was published in March. It lays out several possible recommendations for regulating biotech in the future. For example, one suggestionwhich has the support of many policy folks, including Jaffeis to create a single point of entry for biotech regulation. This could do away with needless regulatory overlap. It would also be easier for companies to navigate.

But the new administration doesnt seem to be paying much attention to any of this. Science and agriculture arent high-priority, if the proposed budget cuts for 2018 are any indication. Trump still hasnt named a science adviser or a director for the OSTP. Some on Team Trump reportedly want to do away with the OSTPa tricky proposal for biotech, since the office organizes and guides the relevant policies and agencies. And its hard to imagine President Trump giving biotech much thought. A search of his tweets, a direct line into his stream of consciousness, shows no mention of genetically modified organisms. Or biotechnology. Or biology.

It could be that the agencies will just plug along under the radar and get some real work done. Or the changes and recommendations will languish, and well be stuck with the 30-year-old coordinated framework. Or the Trump administration could wipe the regulations out completely, like it has with rules on clean water or protecting hibernating bears.

Those last two choicesdoing nothing or wiping out regulations altogetherwould be huge mistakes. Either could allow for a flood of unregulated, and potentially risky, products. It would be much wiser to let the agencies continue the hard work of updating the laws for biological innovations, so we can have confidence to pile a helping of CRISPRd mushroom on our plate.

This article is part of the synthetic biology installment of Futurography, a series in which Future Tense introduces readers to the technologies that will define tomorrow. Each month, well choose a new technology and break it down. Future Tense is a collaboration among Arizona State University, New America, and Slate.

Read the original:
The U.S. Regulations for Biotechnology Are Woefully Out of Date - Slate Magazine

Is this Stock Under $5 a Bargain? Share update on Prana Biotechnology Limited (NASDAQ:PRAN) – Morgan Research

Seasoned investors are often on the lookout for a value name with solid upside. Recently attention has been given to shares of Prana Biotechnology Limited (NASDAQ:PRAN) as the stock recently touched$2.93, a3.17% move from the most recent open.

Sometimes the stock market can be very confusing, even for the most seasoned investors. Even when expectations are met as predicted, the market may decide to move otherwise. This can cause uncertainty and second guessing. Keeping up with historical data as well as short-term and long-term trends may be very helpful. Over the past week, Prana Biotechnology Limited (NASDAQ:PRAN) shares have performed 4.27%. Pushing back over the last quarter, shares are 17.20%. Looking at stock performance for the past six months, shares are -4.25%. Since the start of the calendar year, shares have performed 79.75%.

Is Prana Biotechnology Limited Ready to Move higher? Sign Up For Breaking Alerts on this Stock Before the Crowd.

Lets take a quick look at some possible support and resistence levels for the stock. According to a recent spotcheck, company Prana Biotechnology Limited (NASDAQ:PRAN) have been seen trading -36.03% away from the 50- day high. On the opposite end, shares have been trading 43.63% away from the 50-day low price. Taking a wider perspective, shares have been recently trading -56.20% off the 52-week high and 92.76% away from the 52-week low.

Of course, there is no easy answer to solving the tough question of how to best approach the stock market, especially when dealing with a turbulent investing climate. There are many different schools of thought when it comes to trading equities. Investors may have to first asses their appetite for risk in order to form a solid platform on which to construct a legitimate strategy. Does one run with the bulls and roar with the bears? Do they go against the grain and form a contrarian investing plan? The abundance of information with relatively easy access has made the road a bit smoother to walk for novice investors. Making the transition to the next level is where the champions are able to separate themselves from the pretenders.

Read more:
Is this Stock Under $5 a Bargain? Share update on Prana Biotechnology Limited (NASDAQ:PRAN) - Morgan Research

Favorable Media Coverage Likely to Affect Puma Biotechnology … – The Cerbat Gem


Transcript Daily
Favorable Media Coverage Likely to Affect Puma Biotechnology ...
The Cerbat Gem
Puma Biotechnology logo Headlines about Puma Biotechnology (NYSE:PBYI) have been trending positive recently, according to AlphaOne. AlphaOne ...
Value Composition in Focus For Puma Biotechnology, Inc. - TCTTCT

all 4 news articles »

Read the original:
Favorable Media Coverage Likely to Affect Puma Biotechnology ... - The Cerbat Gem

March for Science: Agony and ecstasy of a Malaysian agricultural biotechnology science communicator – Genetic Literacy Project

What can be more challenging than slogging in the laboratory, burning the midnight Bunsen burner, changing the methodology a few times, dealing with contaminated cell cultures and losing them, not having the transferred genes express themselves, and mining large genomics data in the terabytes?

It is communicating the science behind the research, repackaging it into plain language and dispelling the misinformation created by technology skeptics to ensure that viable science projects that help address food security and sustainable agriculture practices are commercialized, approved and reach the farms and our forks. This is no small task. Science communication is a complex field requiring special skills, training and experience. The heterogeneity of the public makes science communication both challenging and exciting. There is no cookie-cutter approach. Every audience, topic and concern must be approached differently. Each one is unique, requiring a customized communication strategy.

I have been a science communicator for 14 years and I have enjoyed every one of them, although it is not a bed of roses all the time. It requires patience and the ability to learn from our past mistakes and to perfect our techniques. Here I am sharing my agony and ecstasy.

The agony

Why is it that when scientists speak up for genetically modified (GM) crops we are immediately labeled as industry advocates and as recipients of industry money? In contrast, those who evangelize about organic products are seen as angels and saints? Yet, many of the critics of GM crops receive financial support from the organic industry and this industry has been no angel to science. Scientists who collaborate with agri-companies or receive funding from them are also demonized and their credibility trashed by critics. But, industry collaboration is not new in research at universities. The organic industry widely funds research. Why are only agribiotechnology scientists singled out?

Mahaletchumy Arujanan

Critics create myths about organic foods; instill guilt in mothers who dont feed their families with organic foods; and force consumers to pay hefty premiums in the pretext of serving more nutritious and sustainably grown foods. The claims that organic foods are more nutritious have been debunked many times. In spite of all this, GM crops and those who support them are painted as evil. For these reasons, I avoid organic foods like the plague it simply goes against my conscience.

Why is our job made so difficult while critics of GM crops have it easy? They create fear, doubts and myths. But those who embrace science take years to challenge the myths and doubts created by others. It takes years of research. Every time a doubt is created and turned into an unnecessary regulation, farmers pay the price in terms of economic losses. A good example is the failure to approve and commercialize insect resistant Bt brinjal in the Philippines (note the benefits were publicly acknowledged seven years ago but opponents successfully blocked its approval) and GM mustard in India.

It is not easy fighting ideology and hypocrisy with science. The opposition to GM crops has become a cult that no amount of science can dispel. I feel helpless when powerful tools are confiscated from farmers (see how EU Urges the G8 member states not to support GMO crops in Africaclause 72). They are deprived of technological innovations that could help them practice agriculture sustainably, prevent occupational hazards that are caused by the use of pesticides, increase their income and reduce their loss and costs.

A common accusation by critics is that GM seeds are patented by big agri-companies. But they fail to acknowledge that organic products are patented as well. Another favorite of scaremongers is that GM crops are dangerous and can even kill. Yet, since 1996 not a single GM-related health hazard has been reported. Not one. We cant however, say the same for organic produce. Read here, here and here to see the reality of safety of organic foods.

In spite of the mounting evidence on the benefits of GM crops, critics confuse the public with cooked-up evidence demonizing GM crops. For a science communicator backed by science, this is agonizing and makes my job extremely difficult.

The Ecstasy

When Malaysia was developing its Biosafety Act, I was involved in creating awareness about the need for a balanced, science-based regulatory instrument. I faced character assassination, accusations and sarcastic remarks.They were agonizing moments. But the agony turned to ecstasy when the act, and later the regulations and guidelines, became more science-based. Today, I sit in many meetings with the Ministry of Natural Resources and Environment to help implement the regulations in a balanced manner.

There have been other moments of ecstasy as well. Years ago, I waded into untested waters when I tackled issues related to Islamic principles (Shariah compliance) and GM foods. As a non-Muslim, I took a risk in handling such a sensitive topic but there were many countries that were contemplating a fatwa (decree) against GM crops, i.e. to declare GM foods and crops as haram (non-permissible). I didnt want the misinformation to spread among Muslim countries so I organized a dialogue between religious scholars and scientists.

The first meeting collapsed halfway through with many accusations hurled at me by GM opponents. I took a break from this topic for a while and analyzed my mistakes, found new credible partners and organized another high-level dialogue with top Islamic scholars from the Muslim world. It was a huge success. Here is the resolution that is used as a reference in many countries today that resulted from the discussion. Philippines became the first country after the dialogue to reverse its anti-GM rules, where initially they had a blanket decree claiming all GM foods were haram.

In 2010, I took a creative approach to educating a group that otherwise wouldnt take a second look at biotechnology fashion students, and through them a wider womens group. I engaged a university and got its fashion students to design outfits based on biotechnology themes and organized a fashion show. This was part of a bigger event called Bio Carnival with poster drawings, coloring, public speaking, debate, quizzes and spelling competitions for students, and exhibitions and hands-on sessions for the public. It was a rewarding experience when the university later introduced biotechnology as a special project for fashion students after realizing how it inspired fashion designs through its colors and unique patterns. With this approach, all the students had to search for information on biotechnology and we educated them about science and innovation.

Then there is my favorite project. I was long frustrated with the amount of space the mainstream media devoted to science issues. I tried making friends with journalists and organizing media training for scientists but it really did not effect much change. So, I decided to create my own playing field, The Petri Dish the first science newspaper in Malaysia. It is now seven years old and this year it graduated to become a digital portal to reach a wider audience.

The Petri Dish reaches all key stakeholders in Malaysia academia, researchers, policymakers, politicians (all cabinet members receive a copy), students, industry and the general public. We make it available at shopping malls and Starbucks outlets. I know a number of ministers who read it, and once a topic was fiercely debated at the cabinet meeting after being reported in The Petri Dish.

This is our initiative in bringing science to the headlines. It is aimed at creating awareness among all stakeholders on biotechnology so the public will be more receptive to emerging technologies and policymakers will be able to make informed decisions on regulations and funding. It also encourages young people to pursue STEM education and careers. Every time, I receive positive feedback on Petri Dish, I feel a rush of ecstasy. It is a struggle to sustain a science newspaper but the feeling of inspiring people about science is rewarding.

Another area I enjoy is talking to students both at schools and universities. These are uncorrupted minds and they are receptive to information backed by science when it is presented by a credible person. Every year, I reach out to more than 2000 students who are inspired by science and believe it offers solutions to many global problems.

The biggest lesson I have learned is that we need to build trust with our audiences before we start communicating with them: Connecting first and then communicating.

I believe the agony and ecstasy will continue, with exciting new developments in synthetic biology, gene editing and gene drives.

Mahaletchumy Arujanan is the Executive Director of Malaysian Biotechnology Information Centre (MABIC) and Editor-in-Chief of The Petri Dish the first science newspaper in Malaysia. She is also an Adjunct Lecturer at Monash University Malaysia. She has a degree in Biochemistry and Microbiology from Universiti Putra Malaysia, Masters in Biotechnology and PhD in science communication from the University of Malaya. She is an active science communicator who addresses policies, regulations, ethics, religions, STEM and other areas pertinent to biotechnology development. You can follow her onFacebook and Twitter @maha_mabic.

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Original post:
March for Science: Agony and ecstasy of a Malaysian agricultural biotechnology science communicator - Genetic Literacy Project

iShares NASDAQ Biotechnology Index (IBB) Getting Very Favorable Press Coverage, AlphaOne Reports – The Cerbat Gem


Breaking Finance News
iShares NASDAQ Biotechnology Index (IBB) Getting Very Favorable Press Coverage, AlphaOne Reports
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo News coverage about iShares NASDAQ Biotechnology Index (NASDAQ:IBB) has trended very positive this week, according to Alpha One Sentiment. Alpha One, a service of Accern, scores the sentiment of media ...
iShares NASDAQ Biotechnology Index (IBB) Upgraded to Overweight by Credit Suisse Group AGSports Perspectives
iShares NASDAQ Biotechnology Index (IBB) Rating Increased to Buy at Vetr Inc.BBNS
iShares NASDAQ Biotechnology Index (IBB) Upgraded by Vetr Inc. to BuyTranscript Daily
Breaking Finance News
all 17 news articles »

Read more from the original source:
iShares NASDAQ Biotechnology Index (IBB) Getting Very Favorable Press Coverage, AlphaOne Reports - The Cerbat Gem

BioTalent Canada’s Animation to Promote Accessibility in … – Yahoo Finance

OTTAWA, Ontario--(BUSINESS WIRE)--

BioTalent Canada announced today that its animated short, Expanding Accessibility in Biotechnology, has won the Platinum Award for Motion Graphics Information at the 2017 Hermes Creative Awards, an international competition overseen by the Association of Marketing and Communications Professionals (AMCP). The award showcases the talent and creativity of marketing and communications professionals, many of whom have contributed to public service or charitable organizations.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170420005937/en/

Expanding Accessibility in Biotechnology was created as part of BioTalent Canadas Accessibility for Ontarians with Disabilities Act (AODA) employer-awareness campaign, launched in 2016 and funded in part through the Government of Ontarios EnAbling Change Program. The campaign aims to reach and educate bio-economy employers on compliance with the new AODA accessibility standards.

As a national non-profit HR association for the Canadian biotechnology industry, BioTalent Canada works to ensure that the bio-economy has access to the talent it needs. According to research by the organization, only 7.6% of bio-economy companies had persons with disabilities on staff.

BioTalent Canadas animation seeks to increase awareness among employers on the importance of persons with disabilities as a strategically valuable labour market for Canadas biotechnology sector. Developed by eSolutions Group, the animation addresses the importance of creating an inclusive and diverse workforce, which in turn strengthens an organizations innovation.

Canadians with disabilities represent a valuable labour market, one which is under-represented in the bio-economy, says Rob Henderson, BioTalent Canadas President and CEO. It is encouraging to see an animation focused on the benefits of diversity win this award and get showcased at an international level.

Along with the animated short, BioTalent Canada is hosting events across Ontario to educate and train employers on AODAs accessibility standards and what they need to do to comply. The next event will be taking place on April 25th, in the heart of the City of Mississaugas life sciences core.

For more information on the Expanding Accessibility in Biotechnology event in Mississauga, or to register, visit BioTalent Canadas event page.

About BioTalent Canada

BioTalent Canada is the HR partner of Canadas bio-economy. As an HR expert and national non-profit organization, BioTalent Canada focuses on building partnerships and skills for Canadas bio-economy to ensure the industry has access to job-ready people. Through projects, research and product development BioTalent Canada connects employers with job seekers, delivers human resource information and skills development tools so the industry can focus on strengthening Canadas biotech business. For more information, please visit biotalent.ca.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170420005937/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20170420005937/en/

Read more from the original source:
BioTalent Canada's Animation to Promote Accessibility in ... - Yahoo Finance

Biotech Blog: Update on Government Activities on Agricultural Biotechnology in 2020 – CSPI Newsroom

While much of the federal governments recent activity has surrounded COVID-19, some agencies are continuing their work in other areas, including agricultural biotechnology. In this blog, I invite you to take a break from the coronavirus news cycle as I summarize three developments you may have missed that have occurred in agricultural biotechnology in the United States since the start of 2020.

On March 30th, the Environmental Protection Agency (EPA) approved the herbicide Isoxaflutole for use on soybeans that were genetically engineered to be resistant to that herbicide (the soybean variety was approved by the US Department of Agriculture (USDA) years earlier). EPA concluded that under certain conditions, the herbicide could be used in an environmentally protective manner in certain parts of the country. The EPA registration classifies Isoxaflutole as a restricted-use pesticide, which means it can only be applied by applicators who receive special training, and it cannot be applied aerially or through irrigation systems. Geographically, its use on soybeans is limited to specific counties in 25 states (because those areas do not have endangered species that would have required EPA to conduct a detailed assessment to comply with the Endangered Species Act). The registration is limited to five years, which will allow EPA to review compliance with the use restrictions and monitor development of any resistant weeds. EPA also requires the registrant (Bayer CropScience) to establish a weed resistance management plan, including development and implementation of an education program encouraging farmers using the herbicide to take steps to prevent resistant weed development.

While safe and effective herbicides are necessary to produce our food, this registration raises some obvious compliance issues. First, Isoxaflutole was not approved for use in Illinois and Iowa, two of the largest growers of soybeans. Isoxaflutole is also approved for use as a pre-emergence herbicide on corn fields in 8 additional states where it is not approved for use on the herbicide-tolerant GE soybeans (and its use has been banned by state regulators in some counties in some Minnesota, Wisconsin, and Michigan to prevent groundwater contamination). How will EPA ensure that this herbicide is only used on soybeans in geographically approved regions of the country? The situation seems ripe for illegal use by some farmers.

Second, while I applaud EPAs inclusion on the label of actions to be carried out by the developer and farmers to prevent resistant weed development, those actions are not enough. The Isoxaflutole label only states that Appropriate resistance management strategies should be followed and that to delay resistance, take one or more of the following steps. Those statements suggest, but do not legally obligate, farmers to carry out activities such as pesticide rotations from season to season or adoption of integrated weed management programs. Farmers could comply just by switching to a different herbicide if resistant weeds develop or by reporting any suspected resistance to the developer (two of the actions suggested by EPA on the pesticide label under resistance management)but even those are not required. Given the history of overuse of glyphosate by farmers growing GE corn and soybeans, which has resulted in millions of acres of resistant weeds, EPA registration should have explicitly required resistant weed prevention by farmers.

On March 4th, the Food and Drug Administration (FDA) launched its Feed Your Mind website, which is the first public-facing product from the $7.5 million that Congress appropriated starting in 2017 for an Agricultural Biotechnology Education and Outreach Initiative. According to FDA, the initiatives goal is toshare science-based information that educates, informs, and broadens understanding about agricultural biotechnology for consumers. Congress (and the special interests that lobbied for the appropriation) clearly intended to use the authoritative voice of FDA to increase consumers understanding of agricultural biotechnology and correct misconceptions and misinformation.

The initiatives website includes fact sheets, infographics, and videos. It will be followed by additional materials for middle school classrooms, resources for health professionals, and consumer materials later in 2020 and in 2021.

In reviewing Feed Your Mind, one finds information that is scientifically accurate (with reliable references) and relatively easy for a non-scientist to understand. If you know nothing about GMOs and read the websites contents, you will clearly be better informed about what GMOs are, although not necessarily about why GMOs have been so controversial. The question that remains is how this website (which is not easy to find from FDAs homepage, nor does it quickly appear when entering basic questions about GMOs into an internet search engine) will educate a significant segment of American consumers. Will FDA promote the website and its materials through an ad campaign? Will they send emails or postcards to Americans telling them to visit the website?I cannot imagine that the average American consumer visits FDAs website with any great frequency. One can reasonably assume that the number of consumers who will search for the Feed Your Mind website, even if they know it exists, will be extremely small. So far, FDA has only announced the website to its list of stakeholders. Much more outreach will be needed if the information they have generated is to have the impact Congress intended

On March 19th, the Department of Interiors Fish and Wildlife Service (FWS) announced that it had completed a draft Programmatic Environmental Assessment (PEA) to assess the use of GE crops for natural resource management in the National Wildlife Refuge System. The public comment period on the PEA ended April 19th.

Lets explain how we got here. Currently, approximately 28,000 acres of refuge land in the Southeast is contracted out by FWS to farmers who grow primarily corn, soybeans and rice. In those contracts, farmers agree not to harvest 25% of their crop so it can be left as food consumed by waterfowl and other animals that the refuges support. Agricultural fields also maintain open habitat to support wildlife and control invasive species. Contract farmers utilized GE crops until 2012, when a lawsuit stopped the practice pending a PEA in compliance with the National Environmental Policy Act (NEPA). This PEA is the result of that process.

The PEA covers ten states and two territories in the Southeastern United States and recommends a policy that would allow the growing of GE crops on NWR land. The PEA compares the period before 2012 (with GE crops) and after 2012 (without them). They find that the pesticide use (pounds of active ingredient) increased 68% after farmers stopped using GE crops in 2012 and the number of active ingredients increased 76%. Other facts supporting the PEAs conclusion that the growing of GE crops should be allowed include findings that NWR staffs workload was less when farmers used GE crops and farmers had increased yields. Finally, they found using GE crops was consistent with the FWSs Integrated Pest Management Policies.

In the United States, farmers have grown GE crops for more than twenty years, reaping their benefits such as reduced insecticide use on corn and cotton crops while managing their risks (although not always well). If those same GE crops can be beneficial to farmers growing crops on NWR lands without demonstrable risk, as the PEA appears to show, then it seems like they should be permitted to plant them.

After reviewing the comments received, FWS will issue a final PEA. But the process does not end there. The PEA is necessary, but not sufficient for permitting the growing of GE crops in NWRs. Next, individual refuges in the Southeastern region can conduct their own site-specific analysis to determine whether to authorize their farmers to use a GE crop.

Now that youre caught up on the latest in agricultural biotechnology, stay tuned for additional developments we expect in the coming weeks. These include USDAs revisions to 7 C.F.R. Part 340 addressing its oversight of GE organisms that might be plant pests, and EPAs proposal on how its regulation of plant-incorporated protectants will apply to genome-edited crops. Check back with the Biotech Blog for coverage of these and more!

See original here:
Biotech Blog: Update on Government Activities on Agricultural Biotechnology in 2020 - CSPI Newsroom

BIO Announces Educational Sessions for 2017 BIO World Congress … – Business Wire (press release)

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) today announced education program session titles and speakers for the 2017 BIO World Congress on Industrial Biotechnology. The education program features seven diverse content tracks with speakers from around the world over three days of the conference. The worlds largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrs de Montral in Montral, Qubec, Canada.

Brent Erickson, executive vice president of BIOs Industrial & Environmental Section, stated, BIOs 2017 World Congress will feature the most diverse group of speakers and presenters in the conferences history, with scientists and executives from start-up companies, investors from the finance sector, consumer product manufacturers and government officials from across Canada, Europe, the United States and Asia. The education program and partnering system provide a unique forum for conference attendees to share the latest advances in renewable chemicals, synthetic biology, enzymes, food ingredients, fragrances, flavors, cosmetics, biofuels and biorefineries, agricultural crops and biobased materials.

Sessions featuring Renewable Chemicals and Biobased Materials include:

A Revolution in Biobased Products and Packaging Wed. July 26, 11:45 am

Renewable Chemicals and Thermoplastics for Performance Materials Mon. July 24, 10:30 AM

Scaling Novel and Innovative Processes for Commercialization Mon. July 24, 1:45 PM

Meeting Brand Owner and Retailer Demand for Green Chemicals, Materials, and Products Wed. July 26, 10:30 AM

Industrial Synergies and the Circular Economy Wed. July 26, 10:30 AM

All programs at the 2017 BIO World Congress on Industrial Biotechnology are open to members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

For more information on the conference please visit https://www.bio.org/events/bio-world-congress. For assistance, please contact worldcongress@bio.org.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO International Convention June 19-22, 2017 San Diego, Calif.

BIO World Congress on Industrial Biotechnology July 23-26, 2017 Montreal, Canada

See the original post here:
BIO Announces Educational Sessions for 2017 BIO World Congress ... - Business Wire (press release)

Vir Biotechnology Partners with NIH and Biogen for Developing Coronavirus Antibodies – HospiMedica

Vir Biotechnology, Inc. (San Francisco, CA, USA) has entered into a collaboration with Biogen Inc. (Cambridge, MA, USA) for the development and clinical manufacturing of human monoclonal antibodies (mAbs) for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus.

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. The company has identified a number of mAbs that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

Due to the urgency of the situation, Vir and Biogen have begun work while a Clinical Development and Manufacturing Agreement is being negotiated. Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Virs proprietary antibodies.

These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good, said George Scangos, Ph.D., CEO, Vir. Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.

Similarly, Vir has also entered into a research collaboration agreement with the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) to advance characterization and development of mAbs against coronaviruses. The joint project will augment ongoing efforts by both parties to identify antibodies that can be used to prevent or treat infection with existing and emerging viruses and help inform the development of vaccines. Vir and NIAID will work together to identify and optimize combinations of antibodies against coronaviruses, including SARS-CoV-2, SARS and MERS, as well as antibodies that may be effective across additional types of coronaviruses. The two parties will exchange antibodies and other materials for testing in combination and individually and, by mutual agreement, will perform in vivo animal studies to analyze immune responses.

This collaboration expands Virs efforts to characterize and develop antibody therapies against coronaviruses by allowing us to access the VRCs significant and broad research experience with coronaviruses, which is complementary to ours, said Herbert Skip Virgin, M.D., Ph.D., Chief Scientific Officer, Vir. This is one of multiple approaches we are taking to rapidly identify and test potential prophylactics and therapeutics for COVID-19 and we expect it to allow us to accelerate finding solutions to this urgent public health need.

Related Links:Vir Biotechnology, Inc. Biogen Inc.

More here:
Vir Biotechnology Partners with NIH and Biogen for Developing Coronavirus Antibodies - HospiMedica

Is Intrexon Corp (XON) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

The 30 rating InvestorsObserver gives to Intrexon Corp (XON) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 16 percent of stocks in the Biotechnology industry, XONs 30 overall rating means the stock scores better than 30 percent of all stocks.

Click Here to get the full Stock Score Report on Intrexon Corp (XON) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Intrexon Corp (XON) stock has fallen -5.84% while the S&P 500 is up 0.36% as of 11:35 AM on Wednesday, Jan 15. XON is down -$0.42 from the previous closing price of $7.19 on volume of 713,062 shares. Over the past year the S&P 500 is up 26.23% while XON is down -17.74%. XON lost -$3.58 per share the over the last 12 months.

To screen for more stocks like XON click here.

See original here:
Is Intrexon Corp (XON) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear in China – BioSpace

STOCKHOLM, Feb. 24, 2020 /PRNewswire/-- Medivir AB (Nasdaq Stockholm: MVIR)announces today that the company has signed a licensing agreement for Medivir's Xerclear for labial herpes with the Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB). The agreement gives SYB the right to register, manufacture and market the product in China. After market registration and production in China, Medivir will receive a fixed royalty for each unit sold and the agreement guarantees a minimum sale during the first three years on the market amounting to single-digit million amounts in SEK.

For further information, please contact:Uli Hacksell, CEO, Medivir AB, phone: +46-(0)8-5468-3100.

About XerclearIn 2009, Xerclear (Zoviduo) was approved for the treatment of labial herpes. The marketing rights to Xerclear in the USA, Canada and Mexico were divested in 2010, while the corresponding rights in Europe and the rest of the world have been out-licensed to GlaxoSmithKline, with the exception of China and South America where Medivir has retained the rights. Medivir receives royalties on sales of Zoviduo from GlaxoSmithKline. In addition, Medivir would receive milestones when Zoviduo is approved as an over the counter product in certain European markets.

About MedivirMedivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. http://www.medivir.com.

About Shijiazhuang Yuanmai Biotechnology Co LtdShijiazhuang Yuanmai Biotechnology is a wholly owned subsidiary of Shijiazhuang Yuanjia Biotechnology Co. Ltd. Shijiazhuang Yuanjia Biotechnology Co. Ltd. (`Yuanjia Bio') is an international pharmaceutical company established in the Chinese market. The mission of the company to introduce medicinal products, which have been approved in the EU or USA, to China. The management of Yuanjia Bio is from the senior management team of Jiangxi Jiminkexin - one of the top ten pharmaceutical companies in China. Yuanjia Bio has its own professional and experienced clinical and registration team, and it has a good working relationship with the National Drug Evaluation Center and the Registration Division of the National Medicinal Products Agency (formerly CFDA). Yuanjia Bio has an excellent marketing and sales network in China. The sales network covers all provinces and regions in the country, covering more than 2,000 hospitals. The sales organization is very experienced, and it has an excellent track record in building blockbuster products (more than 1 billion RMB of annual sales). Yuanjia Bio's core management team has experience from many cases of successfully introducing overseas products to the Chinese market. Furthermore, it has valuable experience from overseas collaborations, such as the licensing agreement with LIDDS AB (Upsala, Sweden) in the field of prostate cancer in 2017 and exclusive distribution agreement with Peptonic Medical AB (Bromma Sweden) for the product VagiVitalTM in women's health in 2019.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-and-shijiazhuang-yuanmai-biotechnology-sign-licensing-agreement-regarding-manufacturing-and-,c3044319

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/medivir-and-shijiazhuang-yuanmai-biotechnology-sign-licensing-agreement-regarding-manufacturing-and-sales-of-xerclear-in-china-301009902.html

SOURCE Medivir

Read the original here:
Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear in China - BioSpace

Boosting food production through biotechnology – The Nation Newspaper

Experts are advocating the use of biosciences to bring about economic transformation. They believe science-based agricultural products and processes can eliminate hunger, malnutrition and boost produce resilience to climate change-related impacts. One of the approaches is biotechnology, which is the use of scientific tools and techniques to boost food production, DANIEL ESSIET reports.

Nigeria has the largest population in Africa, and it is growing at 3.2 per cent a year.

According to the United Nations (UN) projections for West Africa, Nigeria will be the worlds third most populous country by 2050. Similarly, the United States Census Bureau said there will be an estimated 402 million people in Nigeria in 2050.

For analysts, it is going to be a serious challenge feeding an amazing growing population if new agricultural technologies are not adopted to boost production.

Agricultural experts have recommended that the government should be more proactive in using science, technology and innovationespecially biotechnologyto address food security challenges facing the continent. Hence, there has been increased campaign for biotechnology.

Experts believe biotechnology innovations can enhance productivity and boost food security.

Commonly, biotechnology involves the use of tools and techniques involving biological or chemical processes to boost food production. It is a broad category involving many types of technology and science, including breeding, genetics, microbiome research, and animal health and nutrition.

Agribusinesses have been innovating in biotech for many decades to increase and protect crop yields with fertiliser, crop protection products such as pesticides and improved seeds.

With the population of Nigeria projected to reach 402 million by 2050 and agriculture struggling to adapt to climate change, the pressure to meet the increasing demand for staple foods, including soya beans and maize, has raised interest in safe biotechnologys ability to boost yield.

One of the farmers pushing for safe use of biotechnology is Innocent Mokidi. He is Chief Executive, Brote Urban Vegetable Farm and Processing Limited. He runs large farms in Abuja and Nassarawa State.

He has managed farms where improved soya beans and maize varieties have outperformed conventional seeds per hectare. He has seen maize yielding 10 tonnes per hectare.

While he has made a huge success in agriculture, he is concerned about many Nigerian farmers that eke out a living from small plots of poor soils. Also, crop yields from such farmlands are stagnant and poor .

The only way they can grow more food and have a surplus for sale, according to him, is for the government to promote safe biotechnology in form of improved plant seeds.

As staple foods provide vital nutrients and health benefits, making up close to two-thirds of the nations food intake, Mokidi urged the government and the private sector to tackle food insecurity through improved nutrient-rich, high-yielding varieties and sustainable agronomic practices, ensuring that those who most depend on agriculture have enough to make a living and feed their families.

He wants scientists to develop technologies that can contribute to food security and prosperity among farmers.

In addition to achieving higher yields and reducing pesticide use, farmers such as Mokidi want maize free of the mold that produces aflatoxin, a naturally occurring cancer-causing toxin frequently found in grain products.

A senior lecturer, Department of Crop Science and Biotechnology, Faculty of Agriculture & Veterinary, Imo State University (IMSU) Prof. Martin Onuh, said there was need to deploy biotechnology innovations to make life better for farmers through seeds that produce higher than usual yields with fewer inputs.

He advocated the adoption of responsible breeding technologies to meet most of the Sustainable Development Goals (SDG) targets linked to hunger, food security and nutrition.

In Nigeria, biotechnology tools have been used to improve crops. Maize, sorghum, cowpea and groundnut are the major crops covered by plant breeding activities.

A senior scientist at the International Institute of Tropical Agriculture (IITA), Dr Chiedozie Egesi, is leading a research team developing and releasing several improved varieties of cassava, including one fortified with vitamin A. They are part of the Next Generation Cassava Breeding project (NextGen Cassava), an initiative funded by the Bill & Melinda Gates Foundation and UK Aid from the United Kingdom.

Researchers engaged in the project, which began in 2012 and runs through 2023, have made major strides in understanding cassavas genome and flowering. This has allowed them to shorten the time it takes to develop hardier new cassava varieties that improve yields.

All over Africa, experts are calling for investment in biotechnology. One of them is the President of Alliance for a Green Revolution in Africa (AGRA) Dr. Agnes Kalibata .She has urged intensification of collective efforts towards the eradication of hunger and malnutrition by 2025.

Kalibata said AGRAs mission is to develop practical solutions to significantly boost farm productivity and incomes for the poor while safeguarding the environment, working across all key aspects of the African agricultural value chain from seeds, soil health and water to markets and agricultural education.

AGRAs work primarily focuses on smallholder farmers men and women who typically cultivate staple crops on two hectares or less. In the new strategy for 2017-2021, AGRA is supporting 11 African countries and 30 million smallholder farm households (150 million individuals) to increase their incomes and improve their food security.

This year, AGRA, Syngenta and Syngenta Foundation for Sustainable Agriculture (SFSA) have signed an agreement to work together towards their shared vision of transforming Africas agriculture.

Specifically, the three institutions will work to give farmers access to: yield-enhancing technologies including high-quality seeds, good agriculture practices, and post-harvest management.

Another crusader on the continental front is the Director, Agriculture School, UM6P Agriculture School, and Prof Aziz Yasri. He said there was a need for universities in Africa to work together to build capacities in agricultural technology and to support skills development for employability and entrepreneurship.

He said UM6P is willing to work with other universities to promote business prospect in agriculture while applying and utilising science, technology and innovation (STI).

To promote increased use of biotechnology to boost food production, the university has received funding for agriculture research to help farmers on the continent.

UM6P and OCP, Moroccos phosphates and Fertiliser Company, have signed an agreement with Spanish company Fertinagro Biotech, part of the Trvalis Group to use biotechnology to grow more food.

The goal is to train researchers who subsequently serve in companies that provide sustainable solutions for the development of African and world agriculture and livestock.

The agreement will involve the training of researchers who will seek and develop innovation projects in fields such as sustainability and development, based on actions that promote the circular economy and, at the same time, lead to a well-being for the environment and sustainability.

The collaboration between the institutions also includes connections with Spains leading universities in the fields of agriculture, recycling economy and agro-biosciences.

Under the agreement, OCP will support the project by providing opportunities for practical experience and on the ground testing.

UM6P Secretary-General, Hicham El Habti explained that universitys pioneering role among world-renowned universities in the field. Our objective is to consolidate Moroccos frontline position in R&D, in a unique partnership-based approach and boosting skills training, relevant for the future of Africa, he said.

Read the original post:
Boosting food production through biotechnology - The Nation Newspaper

Biotechnology – Health and Public Services Health … – About ACC

Biotechnology - Health and Public Services Health and Public Services Skip over navigation

The Biotechnology curriculum, which has emerged from molecular biology and chemical engineering, is designed to meet the increasing demands for skilled laboratory technicians in various fields of biological and chemical technology

Course work emphasizes biology, chemistry, mathematics, and technical communications. The curriculum objectives are designed to prepare graduates to serve as research assistants and technicians in laboratory and industrial settings and as quality control/quality assurance technicians.

See our Biotechnology Center of Excellence!

This course introduces the principles and concepts of biology. Emphasis is placed on basic biological chemistry, molecular and cellular biology, metabolism and energy transformation, genetics, evolution, and other related topics. Upon completion, students should be able to demonstrate understanding of life at the molecular and cellular levels.

This course introduces the basic skills and knowledge necessary in a biological or chemical laboratory. Emphasis is placed on good manufacturing practices, safety, sustainable lab practices, solution preparation, and equipment operation and maintenance following standard operating procedures. Upon completion, students should be able to prepare and perform basic laboratory procedures using labware, solutions, and equipment according to prescribed protocols.

This course is designed to develop the ability to produce clear writing in a variety of genres and formats using a recursive process. Emphasis includes inquiry, analysis, effective use of rhetorical strategies, thesis development, audience awareness, and revision. Upon completion, students should be able to produce unified, coherent, well-developed essays using standard written English.

This course covers fundamental principles and laws of chemistry. Topics include measurement, atomic and molecular structure, periodicity, chemical reactions, chemical bonding, stoichiometry, thermochemistry, gas laws, and solutions. Upon completion, students should be able to demonstrate an understanding of fundamental chemical laws and concepts as needed in CHM 152.

This course introduces the fundamental concepts of inorganic chemistry. Topics include measurement, matter and energy, atomic and molecular structure, nuclear chemistry, stoichiometry, chemical formulas and reactions, chemical bonding, gas laws, solutions, and acids and bases. Upon completion, students should be able to demonstrate a basic understanding of chemistry as it applies to other fields.

This course is a laboratory to accompany CHM 131. Emphasis is placed on laboratory experiences that enhance materials presented in CHM 131. Upon completion, students should be able to utilize basic laboratory procedures and apply them to chemical principles presented in CHM 131.

Plan #21 Biotechnology | First Year - Fall 1st Semester

This course is a continuation of BIO 111. Emphasis is placed on organisms, evolution, biodiversity, plant and animal systems, ecology, and other related topics. Upon completion, students should be able to demonstrate comprehension of life at the organismal and ecological levels.

This course covers principles of microbiology and the impact these organisms have on man and the environment. Topics include the various groups of microorganisms, their structure, physiology, genetics, microbial pathogenicity, infectious diseases, immunology, and selected practical applications. Upon completion, students should be able to demonstrate knowledge and skills including microscopy, aseptic technique, staining, culture methods, and identification of microorganisms.

This course covers processes used in the production of biomolecules. Emphasis is placed on the production, characterization, and purification of biological products using fermentation, centrifugation, filtration, electrophoresis, and other techniques used in industry. Upon completion, students should be able to produce biological products using the various methods of bioprocessing.

This course provides a survey of major functional classes of compounds in organic and biochemistry. Topics include structure, properties, and reactions of the major organic and biological molecules and basic principles of metabolism. Upon completion, students should be able to demonstrate an understanding of fundamental chemical concepts needed to pursue studies in related professional fields.

Plan #21 Biotechnology | First Year - Spring 2nd Semester

This course introduces computer concepts, including fundamental functions and operations of the computer. Topics include identification of hardware components, basic computer operations, security issues, and use of software applications. Upon completion, students should be able to demonstrate an understanding of the role and function of computers and use the computer to solve problems.

This course provides a project-based approach to introductory statistics with an emphasis on using real-world data and statistical literacy. Topics include descriptive statistics, correlation and regression, basic probability, discrete and continuous probability distributions, confidence intervals and hypothesis testing. Upon completion, students should be able to use appropriate technology to describe important characteristics of a data set, draw inferences about a population from sample data, and interpret and communicate results.

Plan #21 Biotechnology | First Year - Summer 3rd Semester

This course covers principles of prokaryotic and eukaryotic cell genetics. Emphasis is placed on the molecular basis of heredity, chromosome structure, patterns of Mendelian and non-Mendelian inheritance, evolution, and biotechnological applications. Upon completion, students should be able to recognize and describe genetic phenomena and demonstrate knowledge of important genetic principles.

This course introduces the theory and practices required to successfully initiate and maintain plant and animal cell cultures. Topics include aseptic techniques, the growth environment, routine maintenance of cell cultures, specialized culture techniques, and various applications. Upon completion, students should be able to demonstrate the knowledge and skills required to grow, maintain, and manipulate cells in culture.

This course covers the knowledge and laboratory skills needed to perform chemical analysis. Emphasis is placed on developing laboratory techniques used in the separation, identification, and quantification of selected substances. Upon completion, students should be able to perform laboratory techniques employed in substance identification and volumetric analysis and interpret the results.

This course, the second in a series of two, is designed to teach professional communication skills. Emphasis is placed on research, listening, critical reading and thinking, analysis, interpretation, and design used in oral and written presentations. Upon completion, students should be able to work individually and collaboratively to produce well-designed business and professional written and oral presentations.

This course provides an overview of the basic concepts of communication and the skills necessary to communicate in various contexts. Emphasis is placed on communication theories and techniques used in interpersonal group, public, intercultural, and mass communication situations. Upon completion, students should be able to explain and illustrate the forms and purposes of human communication in a variety of contexts.

This course provides instruction and experience in preparation and delivery of speeches within a public setting and group discussion. Emphasis is placed on research, preparation, delivery, and evaluation of informative, persuasive, and special occasion public speaking. Upon completion, students should be able to prepare and deliver well-organized speeches and participate in group discussion with appropriate audiovisual support.

Plan #21 Biotechnology | Second Year - Fall 4th Semester

This course introduces environmental processes and the influence of human activities upon them. Topics include ecological concepts, population growth, natural resources, and a focus on current environmental problems from scientific, social, political, and economic perspectives. Upon completion, students should be able to demonstrate an understanding of environmental interrelationships and of contemporary environmental issues.

This course provides a laboratory component to complement BIO 140. Emphasis is placed on laboratory and field experience. Upon completion, students should be able to demonstrate a practical understanding of environmental interrelationships and of contemporary environmental issues.

This course provides a comprehensive study of the anatomy and physiology of the human body. Topics include body organization, homeostasis, cytology, histology, and the integumentary, skeletal, muscular, and nervous systems and special senses. Upon completion, students should be able to demonstrate an in-depth understanding of principles of anatomy and physiology and their interrelationships.

This course introduces the current ethics issues surrounding the biotechnology industries. Topics will include risk assessment, the relationships between science, technology, and society, and the effects of new biotechnology products upon the natural world. Upon completion, students should be able to demonstrate knowledge and critical thinking skills in decision-making related to bioethical issues.

This course provides students with experience in molecular techniques employing modern procedures, equipment, and technology. Topics include cloning, sequencing and analysis of DNA samples, PCR/qPCR/RT-PCR, DNA typing (STR analysis), microarrays, and bioinformatics applications. Upon completion, students should be able to discuss and perform advanced genetic, biochemical, and bioinformatic procedures using reagents and equipment according to prescribed protocols.

This course provides a continuation of the study of the fundamental principles and laws of chemistry. Topics include kinetics, equilibrium, ionic and redox equations, acid-base theory, electrochemistry, thermodynamics, introduction to nuclear and organic chemistry, and complex ions. Upon completion, students should be able to demonstrate an understanding of chemical concepts as needed to pursue further study in chemistry and related professional fields.

This course is designed to develop topics which are fundamental to the study of Calculus. Emphasis is placed on solving equations and inequalities, solving systems of equations and inequalities, and analysis of functions (absolute value, radical, polynomial, rational, exponential, and logarithmic) in multiple representations. Upon completion, students should be able to select and use appropriate models and techniques for finding solutions to algebra-related problems with and without technology.

This course covers the principles and practices of modern immunology, including the interactions between the various cellular and chemical components of the immune response. Topics include antigens, humoral immunity, cellular immunity, complement, immunological assays, and hybridoma use and production. Upon completion, students should be able to discuss the immune response, perform immunological assays, and make monoclonal antibody-producing hybridomas.

Plan #21 Biotechnology | Second Year - Spring 5th Semester

This course provides a work-based learning experience with a college-approved employer in an area related to the student's program of study. Emphasis is placed on integrating classroom learning with related work experience. Upon completion, students should be able to evaluate career selection, demonstrate employability skills, and satisfactorily perform work-related competencies.

This course provides an opportunity to pursue an individual laboratory project in biotechnology. Emphasis is placed on developing, performing, and maintaining records of a project in a specific area of interest. Upon completion, students should be able to complete the project with accurate records and demonstrate an understanding of the process.

Plan #21 Biotechnology | Second Year - Summer 6th Semester

This course introduces the principles and concepts of biology. Emphasis is placed on basic biological chemistry, molecular and cellular biology, metabolism and energy transformation, genetics, evolution, and other related topics. Upon completion, students should be able to demonstrate understanding of life at the molecular and cellular levels.

This course introduces the basic skills and knowledge necessary in a biological or chemical laboratory. Emphasis is placed on good manufacturing practices, safety, sustainable lab practices, solution preparation, and equipment operation and maintenance following standard operating procedures. Upon completion, students should be able to prepare and perform basic laboratory procedures using labware, solutions, and equipment according to prescribed protocols.

This course introduces the fundamental concepts of inorganic chemistry. Topics include measurement, matter and energy, atomic and molecular structure, nuclear chemistry, stoichiometry, chemical formulas and reactions, chemical bonding, gas laws, solutions, and acids and bases. Upon completion, students should be able to demonstrate a basic understanding of chemistry as it applies to other fields.

This course is a laboratory to accompany CHM 131. Emphasis is placed on laboratory experiences that enhance materials presented in CHM 131. Upon completion, students should be able to utilize basic laboratory procedures and apply them to chemical principles presented in CHM 131.

This course introduces computer concepts, including fundamental functions and operations of the computer. Topics include identification of hardware components, basic computer operations, security issues, and use of software applications. Upon completion, students should be able to demonstrate an understanding of the role and function of computers and use the computer to solve problems.

Plan #135 Basic Laboratory Certificate

This course introduces the basic skills and knowledge necessary in a biological or chemical laboratory. Emphasis is placed on good manufacturing practices, safety, sustainable lab practices, solution preparation, and equipment operation and maintenance following standard operating procedures. Upon completion, students should be able to prepare and perform basic laboratory procedures using labware, solutions, and equipment according to prescribed protocols.

This course introduces computer programming and problem solving in a structured program logic environment. Topics include language syntax, data types, program organization, problem solving methods, algorithm design, and logic control structures. Upon completion, students should be able to use top-down algorithm design and implement algorithmic solutions in a programming language.

This course introduces database design theories and analyses. Emphasis is placed on data dictionaries, normalization, data integrity, and data modeling. Upon completion, students should be able to design normalized database structures which exhibit data integrity.

This course covers the key technologies used to manipulate, store and analyze big data. Topics include scripting languages, noSQL databases, database scalability, performance metrics and tuning. Upon completion, students should be able to use programming techniques to investigate data sets and algorithms.

Plan #136 Bioinformatics Certificate

F at 12:30 PM - 3:30 PM

H 302

M at 12:45 PM - 3:45 PM

H 302

T at 12:45 PM - 3:45 PM

H 302

W at 12:45 PM - 3:45 PM

H 302

T at 8:30 AM - 11:30 AM

H 302

TH at 12:45 PM - 3:45 PM

H 302

W at 6:00 PM - 9:00 PM

H 302

General Biology I

F at 12:30 PM - 3:30 PM

B B306

TH at 12:45 PM - 3:45 PM

B B306

General Biology II

W at 12:45 PM - 3:45 PM

H 305

T at 12:45 PM - 3:45 PM

H 305

T at 8:30 AM - 11:30 AM

H 305

TH at 8:30 AM - 11:30 AM

H 305

TH at 12:45 PM - 3:45 PM

H 305

W at 6:00 PM - 9:00 PM

H 305

TH at 6:00 PM - 9:00 PM

H 305

Anatomy and Physiology I

M at 12:45 PM - 3:45 PM

H 318

Genetics

TH at 8:30 AM - 11:30 AM

H 302

W at 12:45 PM - 3:45 PM

H 318

Microbiology

Bioethics

T at 12:45 PM - 3:45 PM

H 318

Basic Laboratory Techniques

TH at 9:00 AM - 12:00 PM

H 316

Cell Culture

Object] at -

Read the rest here:
Biotechnology - Health and Public Services Health ... - About ACC

biotechnology | Definition, Examples, & Applications …

Biotechnology, the use of biology to solve problems and make useful products. The most prominent area of biotechnology is the production of therapeutic proteins and other drugs through genetic engineering.

People have been harnessing biological processes to improve their quality of life for some 10,000 years, beginning with the first agricultural communities. Approximately 6,000 years ago, humans began to tap the biological processes of microorganisms in order to make bread, alcoholic beverages, and cheese and to preserve dairy products. But such processes are not what is meant today by biotechnology, a term first widely applied to the molecular and cellular technologies that began to emerge in the 1960s and 70s. A fledgling biotech industry began to coalesce in the mid- to late 1970s, led by Genentech, a pharmaceutical company established in 1976 by Robert A. Swanson and Herbert W. Boyer to commercialize the recombinant DNA technology pioneered by Boyer and Stanley N. Cohen. Early companies such as Genentech, Amgen, Biogen, Cetus, and Genex began by manufacturing genetically engineered substances primarily for medical and environmental uses.

For more than a decade, the biotechnology industry was dominated by recombinant DNA technology, or genetic engineering. This technique consists of splicing the gene for a useful protein (often a human protein) into production cellssuch as yeast, bacteria, or mammalian cells in culturewhich then begin to produce the protein in volume. In the process of splicing a gene into a production cell, a new organism is created. At first, biotechnology investors and researchers were uncertain about whether the courts would permit them to acquire patents on organisms; after all, patents were not allowed on new organisms that happened to be discovered and identified in nature. But, in 1980, the U.S. Supreme Court, in the case of Diamond v. Chakrabarty, resolved the matter by ruling that a live human-made microorganism is patentable subject matter. This decision spawned a wave of new biotechnology firms and the infant industrys first investment boom. In 1982 recombinant insulin became the first product made through genetic engineering to secure approval from the U.S. Food and Drug Administration (FDA). Since then, dozens of genetically engineered protein medications have been commercialized around the world, including recombinant versions of growth hormone, clotting factors, proteins for stimulating the production of red and white blood cells, interferons, and clot-dissolving agents.

In the early years, the main achievement of biotechnology was the ability to produce naturally occurring therapeutic molecules in larger quantities than could be derived from conventional sources such as plasma, animal organs, and human cadavers. Recombinant proteins are also less likely to be contaminated with pathogens or to provoke allergic reactions. Today, biotechnology researchers seek to discover the root molecular causes of disease and to intervene precisely at that level. Sometimes this means producing therapeutic proteins that augment the bodys own supplies or that make up for genetic deficiencies, as in the first generation of biotech medications. (Gene therapyinsertion of genes encoding a needed protein into a patients body or cellsis a related approach.) But the biotechnology industry has also expanded its research into the development of traditional pharmaceuticals and monoclonal antibodies that stop the progress of a disease. Such steps are uncovered through painstaking study of genes (genomics), the proteins that they encode (proteomics), and the larger biological pathways in which they act.

In addition to the tools mentioned above, biotechnology also involves merging biological information with computer technology (bioinformatics), exploring the use of microscopic equipment that can enter the human body (nanotechnology), and possibly applying techniques of stem cell research and cloning to replace dead or defective cells and tissues (regenerative medicine). Companies and academic laboratories integrate these disparate technologies in an effort to analyze downward into molecules and also to synthesize upward from molecular biology toward chemical pathways, tissues, and organs.

In addition to being used in health care, biotechnology has proved helpful in refining industrial processes through the discovery and production of biological enzymes that spark chemical reactions (catalysts); for environmental cleanup, with enzymes that digest contaminants into harmless chemicals and then die after consuming the available food supply; and in agricultural production through genetic engineering.

Agricultural applications of biotechnology have proved the most controversial. Some activists and consumer groups have called for bans on genetically modified organisms (GMOs) or for labeling laws to inform consumers of the growing presence of GMOs in the food supply. In the United States, the introduction of GMOs into agriculture began in 1993, when the FDA approved bovine somatotropin (BST), a growth hormone that boosts milk production in dairy cows. The next year, the FDA approved the first genetically modified whole food, a tomato engineered for a longer shelf life. Since then, regulatory approval in the United States, Europe, and elsewhere has been won by dozens of agricultural GMOs, including crops that produce their own pesticides and crops that survive the application of specific herbicides used to kill weeds. Studies by the United Nations, the U.S. National Academy of Sciences, the European Union, the American Medical Association, U.S. regulatory agencies, and other organizations have found GMO foods to be safe, but skeptics contend that it is still too early to judge the long-term health and ecological effects of such crops. In the late 20th and early 21st centuries, the land area planted in genetically modified crops increased dramatically, from 1.7 million hectares (4.2 million acres) in 1996 to 160 million hectares (395 million acres) by 2011.

Overall, the revenues of U.S. and European biotechnology industries roughly doubled over the five-year period from 1996 through 2000. Rapid growth continued into the 21st century, fueled by the introduction of new products, particularly in health care.

Original post:
biotechnology | Definition, Examples, & Applications ...